ACE031
Soluble activin receptor type IIB fusion protein that acts as a myostatin trap. A single-dose phase 1 study in healthy postmenopausal women reported a 3.3% increase in total lean mass by DXA.
Regulatory status (as of Sept 2026)
No US regulatory status; never approved, development discontinued. Not among the peptides addressed by the April 2026 503A action or the July 2026 PCAC votes.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
ACE-031 is a compound whose development or US marketing has been discontinued. Soluble activin receptor type IIB fusion protein that acts as a myostatin trap.
| Half-life | About 12 days |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Discontinued |
| Dosing | Published research: 0.02-3 mg/kg subcutaneous single dose in 48 healthy postmenopausal women (phase 1) details0.02-3 mg/kg s.c. single dose in 48 healthy postmenopausal women (phase 1); 1-3 mg/kg s.c. every 2-4 weeks in ambulatory boys with DMD (phase 2, stopped early)Community-reportedCommunity-reported: Research varies, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It acts as a decoy that soaks up myostatin, a protein that limits muscle growth. Decoy receptor that binds myostatin and other negative regulators of muscle mass.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, reported doses vary widely (subcutaneous injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| ACE-031 | ~12 days | Subcutaneous injection | Discontinued |
| Follistatin 344 | Unknown | Subcutaneous injection | Preclinical (animal) |
| IGF-1 DES | No published PK data found (des(1-3)IGF-I clears more rapidly than IGF-I in pigs/marmosets, but no published t1/2 value was found) | Intramuscular (site-specific) | Preclinical (animal) |
| IGF-1 LR3 | No published PK data found | Subcutaneous or intramuscular | Preclinical (animal) |
| MGF (Mechano Growth Factor) | No published PK data found | Intramuscular (site-specific) | Preclinical (animal) |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Muscle category. View All Muscle Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.